Connect with us

Technology

Clarivate Announces 15th Annual Pharmavision India Conference Agenda

Published

on

Industry leaders to discuss AI in healthcare, cell and gene therapy, market access and more at premier life sciences event

LONDON, Sept. 18, 2024 /PRNewswire/ — Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the full agenda for the 15th annual Clarivate Pharmavision India conference. The 15th edition of Pharmavision India reinforces the industry’s dedication to patient welfare, highlighting how collective efforts and innovative strategies have transformed the healthcare ecosystem. With a focus on improving patient outcomes and building resilience, the two-day event will take place in Ahmedabad and Hyderabad on September 25-26, 2024.

In a country with billions of people, addressing challenges such as healthcare affordability and access is crucial. Organizations must adopt effective, patient-centric approaches across diverse functions to ensure return on investment and a competitive advantage. As the healthcare landscape evolves, balancing these priorities is essential for sustainable growth and better patient outcomes. Pharmavision India 2024 will provide attendees with the opportunity to tackle the industry’s most urgent challenges in life sciences and healthcare.

Ramandeep Singh, Vice President, Life Sciences and Healthcare, India, Clarivate, said: “Since its inception in 2010, Pharmavision India has been a crucial platform for the pharmaceutical, biotech, and healthcare sectors. It enables industry leaders to align, strategize, and drive growth in a competitive landscape. This event is pivotal for fostering innovation across R&D, generics, biosimilars, and healthcare manufacturing. Our expertise and leadership position us uniquely to lead this conference, advancing industry standards and creating collaboration opportunities.”

Henry Levy, President, Life Sciences and Healthcare, Clarivate, added: “At Clarivate, our mission is to foster collaboration across life sciences and healthcare industries, driving strategies that enhance patient outcomes and sustainable growth. We are proud to bring together industry leaders to tackle the vital challenge of integrating patient-centric innovation in today’s evolving market through impactful forums such as Clarivate Pharmavision India.”

This year’s agenda features insights and perspectives from industry leaders and analysts, with sessions focused on innovative R&D, generics, biosimilars and healthcare manufacturing. Noteworthy sessions include:

Indian Pharma: Generics versus innovation – finding the balance for success, by Dr. Keyur Parekh, President, Corporate Strategy, Zydus Lifesciences LimitedThe role of AI and big data in healthcare: Transformative impacts and future prospects, by Mr. Anirban Roy Chowdhury, Senior General Manager, Amneal PharmaceuticalsCell and gene therapy: Addressing key barriers for successful integration into clinical practice in the Indian context, by Dr. Tulip Nuval, Head of Business Excellence, Intas Pharmaceuticals Limited Cell and gene therapy: Addressing key barriers for successful integration into clinical practice in the Indian context, by Mr. Rebu Ninan, Head of Commercial & Market Access, Immuneel Therapeutics Private LimitedPatients and the LMIC story: How Indian companies drive affordability in the global scenario, by Dr. Rahul Kapur, Head – Medical Affairs (EM) and COE, Biocon Biologics Limited Creating value for patients and stakeholders, by Mr. Deepak Sapra, Chief Executive Officer, API and Services, Dr. Reddy’s Laboratories 

Pharmavision India takes place on Wednesday, September 25, 2024, at the Hyatt Ahmedabad, and Thursday, September 26, 2024, at the Taj Deccan, Hyderabad. Register to attend and learn more on this premier event, here.

Connect with Clarivate Life Sciences and Healthcare. Join the conversation and mention Clarivate and Pharmavision on X and LinkedIn.  #Pharmavision #PatientCare #Biopharma #ThinkForward

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com

Media Contact:
Catherine Daniel
Director External Communications, Life Sciences & Healthcare
newsroom@clarivate.com 

SOURCE Clarivate Plc

Continue Reading

Technology

PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026

Published

on

By

LAS VEGAS, Nov. 21, 2026 /PRNewswire/ — PHONO showcased its diverse solar and energy storage solutions at RE+ 2026, held November 17–19 in Las Vegas, highlighting its latest offerings for residential, commercial, solar carport, and utility-scale applications. Marking its 20th anniversary, PHONO recognized long-standing U.S. customers and explored new opportunities for collaboration. The company also secured 150 MW in new orders during the event, underscoring its continued business momentum and commitment to the U.S. solar market. 

As the U.S. solar market continues to evolve, developers and project owners are placing greater emphasis on supply chain transparency, regulatory compliance, and project economics. In response, PHONO is leveraging its global supply chain capabilities and diversified product portfolio to deliver reliable, cost-effective solutions tailored to the needs of the U.S. market.

Solutions for Diverse Application Scenarios

PHONO showcased a diverse portfolio of solar and energy storage solutions, including the Draco Series 450W True Black module for residential rooftops and the Twinplus Series 550W bifacial module for commercial and industrial applications, featuring a lightweight transparent backsheet and up to 76.8% U.S. domestic content, while the Draco Series 730W bifacial module is designed for high energy yield in utility-scale projects. PHONO also presented its 261 kWh and 932 kWh outdoor energy storage systems, offering flexible solutions for diverse energy needs.

Industry Insights and Market Perspectives

On November 17, PHONO hosted an expert speaker session at its booth, featuring representatives from BloombergNEF, RETC, and Kiwa PVEL. The discussions covered the 2027 U.S. solar market outlook, evolving policies, and PV module reliability, offering valuable market perspectives and technical insights.

Built on Trust, Growing Together

As PHONO celebrated its 20th anniversary, representatives from its eight leading U.S. customers visited the booth to discuss future cooperation. General Manager Zhong Zaifeng presented anniversary awards to long-standing partners in recognition of their continued trust and support.

Despite a challenging market environment, orders from the U.S. market grew approximately 200% year over year in 2026. During RE+ 2026, the company secured 150 MW in new orders, with over 500 MW in its sales pipeline, reflecting continued business momentum in the U.S. market. The awards and new agreements highlighted PHONO’s long-term partnerships and continued commitment to the U.S. market.

Looking ahead, PHONO remains committed to strengthening its product innovation, global supply chain, and local services while building lasting partnerships to support the clean energy transition.

View original content to download multimedia:https://www.prnewswire.com/news-releases/phono-marks-20th-anniversary-and-secures-new-orders-at-re-2026-302947598.html

SOURCE PHONO

Continue Reading

Technology

A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time

Published

on

By

The pet AI startup will demonstrate PettiLive! at CES 2027.

SEATTLE, Nov. 21, 2026 /PRNewswire/ — PettiChat, the Seattle-based pet AI startup behind the world’s first real-time AI pet translator, today announced the launch of PettiLive!, a digital version of each pet that lives in the PettiChat app and on the computer, mirroring the pet’s real life as it happens.

What is PettiLive!

PettiLive! is a digital twin of your pet. Your pet wears a small PettiChat device that tracks what it does throughout the day — running, walking, standing, eating, sleeping, jumping, cleaning itself, and calling out. PettiLive! brings those behaviors to life as a digital pet on your screen, mirroring them in real time. When your pet naps, PettiLive! naps. When your pet runs across the room, PettiLive! runs too. Every movement is driven by your pet’s actual behavior. It is your own pet — its real life, brought into a digital presence.

Because PettiLive! is built around your pet’s real behavior, every digital twin is unique. It continuously learns your pet’s habits: the longer your pet wears the device, the more PettiLive! behaves like your pet. Open the app to see what your pet is doing right now and how its day is unfolding — including activity, meals, rest, and sleep, all measured against its own normal patterns. Whether you are at work, traveling, or simply in the next room, your pet’s daily life is right there on your screen.

PettiChat’s vision: the AI gateway for pets

PettiChat is building the AI gateway for pets, powered by its own pet AI model, PettiWorld. Translation is the first feature PettiChat delivers.

But the vision extends beyond translation: Pet Wellness, built around the pet itself. By tracking eating, playing, sleeping, and daily activity over time, Pet Wellness aims to surface meaningful changes in routines and behavior that owners should pay attention to. PettiLive! is a step toward that vision. The same always-on record of a pet’s life that powers PettiLive! also lays the foundation for longitudinal pet wellness.

One model: PettiWorld

One model powers both experiences. PettiWorld, PettiChat’s self-developed multimodal model for pets, translates pet vocalizations and behaviors into human language while also powering PettiLive!. Trained on 60M+ behavior data points and 10M+ vocalization data points, the model continues to improve — allowing both translation and PettiLive! to get better after launch.

“Owners have always wondered what their pets’ days look like when they are not there,” said Anodime Wen, co-founder of PettiChat. “A camera shows you a room; a tracker shows you a dot. PettiLive! shows you your pet, living its day. That is what it means to build the future of pet care.”

Momentum: from Kickstarter to 20,000 homes — and screens everywhere

Founded in January 2026, PettiChat launched on Kickstarter at the end of April 2026, selling nearly 1,000 units and raising $150K. Since then, more than 20,000 units have reached homes across 120+ countries. PettiChat has also generated more than 500 million impressions on social media, all organic — including individual pet videos that reached 8.1 million views on Instagram and a Polymarket post on X that received 12.2 million views.

PettiLive! is now open to all PettiChat users through the PettiChat app, with the computer version to follow in a month. The PettiChat device ($179) is available on Amazon and at pettichat.com.

PettiChat will exhibit at CES 2027 in Las Vegas and Global Pet Expo 2027 in Orlando.

About PettiChat

PettiChat is a Seattle-based pet AI startup building the future of pet care, powered by PettiWorld, its self-developed multimodal model for pets. Through a small wearable device and app for dogs and cats, PettiChat combines real-time AI translation, PettiLive!, Pet Wellness, and Hybrid Tracking location.

View original content to download multimedia:https://www.prnewswire.com/news-releases/a-seattle-startup-brings-your-pet-to-life-on-your-phone-and-laptop-with-the-avatar-mirroring-their-every-move-in-real-time-302947597.html

SOURCE PettiChat

Continue Reading

Technology

How to Go 2x Long Anthropic (ANT): Leverage Shares by Themes Explains ANUU, the 2x Leveraged Anthropic ETF Launching Monday

Published

on

By

Following Anthropic’s $83-per-share IPO pricing and Nasdaq trading debut at $111.50-per-share on November 19, 2026, Leverage Shares by Themes outlines how investors can gain long exposure to Anthropic stock (ANT), and where its planned 2X Long Anthropic ETF (ANUU) fits into the investment landscape.

GREENWICH, Conn., Nov. 21, 2026 /PRNewswire/ — Leverage Shares by Themes today published a step-by-step guide for investors looking to invest in Anthropic stock following the company’s highly anticipated initial public offering. Anthropic, PBC priced its IPO at $83.00 per share on November 18, 2026, above its initially proposed range of $70 to $78, with the offering totaling approximately $81.3 billion. The company’s Class A common stock began trading on Nasdaq under the ticker ANT on November 19, opening at $111.50 per share. With Anthropic now publicly traded, investors can purchase shares through brokerage accounts, while those seeking leveraged exposure can explore the planned Leverage Shares 2X Long Anthropic Daily ETF (ANUU).

How to Buy Anthropic Stock (ANT) Now That It Is Trading on Nasdaq
Following its IPO on November 19, 2026, investors can buy Anthropic (ANT) shares through a brokerage account that offers Nasdaq-listed stocks.

Step 1: Find Anthropic Stock (ANT) Through Your Brokerage

Search for Anthropic under the ticker ANT in your brokerage account. Investors no longer need to request an IPO allocation, as shares are now available for purchase on the open market during regular trading hours.

Step 2: Check the Current Share Price

Anthropic’s market price may differ significantly from its $83.00 IPO price and can fluctuate throughout the trading day. Review the latest ANT share price before placing an order.

Step 3: Choose How to Buy ANT Shares

Investors can place a market order to buy at the prevailing market price or use a limit order to specify the maximum price they are willing to pay. Given the potential volatility of newly listed stocks, investors should consider the risks of each order type before trading.

Can You Get 2X Long Exposure to Anthropic Stock?
Yes, once it launches: the Leverage Shares 2X Long Anthropic Daily ETF (ANUU) will seek daily investment results, before fees and expenses, corresponding to 200% (2X) of the daily performance of Anthropic common stock.

ANUU is not a way to buy into the IPO itself. The Fund does not take part in the offering and does not hold Anthropic shares. It is designed for knowledgeable investors who want to take a bullish daily view on Anthropic and who monitor their positions actively. Investors with a bearish daily view can use ANDD (2X short) or ANSS (1X short) once they launch.

ANUU, ANDD and ANSS are not yet trading. Their first trading date on Cboe is this coming Monday, November 23, 2026.

Ticker

ETF Name

Underlying
Asset

Exchange

Expense
Ratio

ANUU

Leverage Shares 2X Long Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANDD

Leverage Shares 2X Short Anthropic Daily ETF

Anthropic

Cboe

0.75 %

ANSS

Leverage Shares 1X Short Anthropic Daily ETF

Anthropic

Cboe

0.99 %

“Most of the questions we are getting this week are practical ones: what the ticker is, when the stock opens and how to buy it,” said Paul Marino, Chief Revenue Officer, Themes ETFs. “We want investors to have clear answers first, and to understand that ANUU is a daily 2X tool for active traders, not a substitute for owning Anthropic shares.”

Frequently Asked Questions

What Is Anthropic’s Stock Ticker?
Anthropic’s Class A common stock is expected to trade on the Nasdaq Global Select Market under the ticker ANT. ANUU, ANDD and ANSS are Leverage Shares ETF tickers, not Anthropic’s.

Is ANUU the Same as Buying Anthropic Stock?
No. ANUU will seek 2X the daily move of Anthropic stock, before fees and expenses. It does not give its investors Anthropic shares or shareholder voting rights, and its returns over periods longer than one day can differ significantly from 2X the stock’s return.

For more on how the three ETFs work, see the Leverage Shares research team’s guide, Anthropic Leveraged ETFs Explained: Long And Short 

Fund pages: 2X Long Anthropic ETF (ANUU) | 2X Short Anthropic ETF (ANDD) | 1X Short Anthropic ETF (ANSS)

About Themes ETFs

Themes ETFs is a provider of thematic and single-stock leveraged ETFs, focused on delivering innovative, cost-efficient investment tools that allow investors to access the companies and trends shaping the future. Through its Leverage Shares platform, Themes ETFs offers daily leveraged and inverse ETF strategies designed for sophisticated investors and active traders.

For more information, visit www.themesetfs.com and www.leverageshares.com.

INVESTMENT INVOLVES SIGNIFICANT RISK. Funds do not invest directly in the underlying stock. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

An investor should carefully consider a Fund’s investment objective, risks, charges, and expenses before investing. A Fund’s prospectus and summary prospectus contain this and other information about Themes ETFs. To obtain a Fund’s prospectus and summary prospectus call 866-584-3637. A Fund’s prospectus and summary prospectus should be read carefully before investing.

Newly launched Funds have risks associated with a limited operating history.

Because of daily rebalancing and the compounding of each day’s return over time, the return of a Fund for periods longer than a single day will be the result of each day’s returns compounded over the period, which will very likely differ from the stated multiple or inverse multiple of the return of the underlying stock over the same period. The Funds are not suitable for all investors. The Funds are designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged or inverse investment results, understand the risks associated with the use of leverage and inverse exposure, as applicable, and are willing to monitor their portfolios frequently. The Funds are not intended to be used by, and are not appropriate for, investors who do not intend to actively monitor and manage their portfolios.

Under the Investment Advisory Agreement between the Adviser and the Trust, on behalf of the Funds (the “Investment Advisory Agreement”), the Adviser has agreed to pay all expenses of the Funds, except for the fee paid to the Adviser pursuant to the Investment Advisory Agreement, interest charges on any borrowings, taxes, brokerage commissions and other expenses incurred in placing orders for the purchase and sale of securities and other investment instruments, acquired fund fees and expenses, accrued deferred tax liability, extraordinary expenses, and distribution (12b-1) fees and expenses.

Past performance does not guarantee future results.

INVESTMENT RISKS: Investing in the Funds involves a high degree of risk. As with any investment, there is a risk that you could lose all or a portion of your investment in the Funds.

Investment in leveraged and inverse products may be subject to higher volatility. The Funds do not directly invest in the underlying stock. An investment in a Fund involves risk, including the possible loss of principal. The Funds are non-diversified and include risks associated with concentrating investments in a particular industry, sector, or geographic region, which can result in increased volatility. The use of derivatives such as futures contracts and swaps is subject to market risks that may cause their price to fluctuate over time.

Risks of the Funds include effects of Compounding and Market Volatility Risk, Inverse Risk, Market Risk, Counterparty Risk, Rebalancing Risk, IntraDay Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, and risks specific to the securities of the Underlying Stock and the sector in which it operates. These and other risks can be found in the prospectus.

For periods longer than a single day, the Funds may lose money even if Anthropic’s stock price remains flat or moves in a direction consistent with a Fund’s investment objective. An investor could lose the full principal value of their investment in the Leverage Shares 2x Long Anthropic Daily ETF (ANUU) if Anthropic’s stock price declines by more than 50% in a single trading day, or in the Leverage Shares 2x Short Anthropic Daily ETF (ANDD) if Anthropic’s stock price increases by more than 50% in a single trading day. The Leverage Shares 1x Short Anthropic Daily ETF (ANSS) also carries the risk of substantial or total loss if Anthropic’s stock price rises significantly.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (NBBO) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses, or sales charges. One cannot invest directly in an index.

This information is not an offer to sell or a solicitation of an offer to buy shares of any Funds to any person in any jurisdiction in which an offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction.

Themes Management Company LLC serves as an adviser to the Themes ETFs Trust. The Funds are distributed by ALPS Distributors, Inc. (1290 Broadway, Suite 1000, Denver, Colorado 80203). ALPS is not affiliated with Anthropic or any other mentioned entity. Client brokerage services are not offered by ALPS. Please see third-party sites for more information about any mentioned services.

Themes ETFs are not sponsored, endorsed, issued, sold, or promoted by Anthropic, nor does Anthropic make any representations regarding the advisability of investing in Themes ETFs. Neither ALPS Distributors, Inc., Themes Management Company LLC nor Themes ETFs are affiliated with Anthropic.

Themes Management Company LLC and Leverage Shares are affiliates that are under common control. Themes Management Company LLC and Leverage Shares have entered into a licensing agreement in which Leverage Shares licenses the trademark LEVERAGE SHARES to Themes Management Company LLC for use in financial services in the United States.

View original content:https://www.prnewswire.com/news-releases/how-to-go-2x-long-anthropic-ant-leverage-shares-by-themes-explains-anuu-the-2x-leveraged-anthropic-etf-launching-monday-302947477.html

SOURCE Themes ETFs

Continue Reading

Trending